Literature DB >> 24856644

Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases.

Hong Du1, Haijuan Hu1, Hongmei Zheng1, Jie Hao1, Jingci Yang2, Wei Cui3.   

Abstract

Statins are widely used as hypolipidemic drugs, and have beneficial effects in reducing cardiovascular events. In addition, recent studies on the pleiotropic effects of statins (i.e., simvastatin) reveal that these drugs have many additional anti-atherogenic effects, including antiplatelet activity. The mechanisms may be partly related to activation of peroxisome proliferator-activated receptors (PPARs), which are present in human platelets, and whose activation inhibits platelet aggregation. However, the details of the signaling pathway by which simvastatin inhibits platelet activation via PPARs have not yet been completely established. The aim of this study was to examine the mechanisms by which the PPAR-mediated pathways contribute to the antiplatelet activity of simvastatin. Simvastatin (3-50 μM) induced PPARα and PPARγ activation in a dose-dependent manner in washed platelets. Additionally, simvastatin inhibited collagen-induced platelet aggregation, expression of CD62 and PAC-1, and Ca(2+) mobilization. These effects of simvastatin on platelet responses were strongly reduced by adding a selective PPARγ antagonist (GW9662), but not PPARα antagonist (GW6471). Moreover, in the presence of GW9662, simvastatin-mediated increase of cyclic adenosine monophosphate (cAMP) production, vasodilator-stimulated phosphoprotein (VASP) Ser(157) phosphorylation and inhibition of Akt phosphorylation were markedly reversed. Furthermore, simvastatin was found to inhibit phosphorylation of mitogen-activated protein kinases (MAPKs, i.e., p38 MAPK, ERK) by increasing the association between PPARγ and the components of MAPKs after platelet activation. Taken together, the present results confirm that simvastatin inhibition of platelet activation is mediated by PPARγ-dependent processes, which involves mediating MAPKs signaling, increase of cAMP formation and VASP Ser(157) phosphorylation, inhibition of Akt phosphorylation and intracellular Ca(2+) mobilization.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cyclic adenosine monophosphate; Mitogen-activated protein kinase; Peroxisome proliferator-activated receptor; Platelet activation; Simvastatin; Statin

Mesh:

Substances:

Year:  2014        PMID: 24856644     DOI: 10.1016/j.thromres.2014.05.005

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

1.  Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK.

Authors:  Li Shang; Shu-Shan Jia; Hai-Ming Jiang; Hua Wang; Wen-Hua Xu; Chang-Jun Lv
Journal:  Tumour Biol       Date:  2015-01-29

Review 2.  Pleiotropic effects of statins: new therapeutic targets in drug design.

Authors:  Onkar Bedi; Veena Dhawan; P L Sharma; Puneet Kumar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-05       Impact factor: 3.000

Review 3.  Emerging views of statin pleiotropy and cholesterol lowering.

Authors:  Dongbo Yu; James K Liao
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

4.  Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway.

Authors:  Gang Wang; Rui Cao; Yongzhi Wang; Guofeng Qian; Han C Dan; Wei Jiang; Lingao Ju; Min Wu; Yu Xiao; Xinghuan Wang
Journal:  Sci Rep       Date:  2016-10-25       Impact factor: 4.379

5.  RXR Ligands Negatively Regulate Thrombosis and Hemostasis.

Authors:  Amanda J Unsworth; Gagan D Flora; Parvathy Sasikumar; Alexander P Bye; Tanya Sage; Neline Kriek; Marilena Crescente; Jonathan M Gibbins
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-02       Impact factor: 8.311

6.  Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis.

Authors:  Shuaifei Ji; Babo Zhang; Xianda Wang; Heng Shi; Lixin Yu; Xiaocheng Wang
Journal:  Biosci Rep       Date:  2019-07-25       Impact factor: 3.840

Review 7.  Effect of Statins on Platelet Activation and Function: From Molecular Pathways to Clinical Effects.

Authors:  Antonio Nenna; Francesco Nappi; Mario Lusini; Umberto Maria Satriano; Davide Schilirò; Cristiano Spadaccio; Massimo Chello
Journal:  Biomed Res Int       Date:  2021-01-23       Impact factor: 3.411

Review 8.  Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles.

Authors:  Katie L Lannan; Julie Sahler; Nina Kim; Sherry L Spinelli; Sanjay B Maggirwar; Olivier Garraud; Fabrice Cognasse; Neil Blumberg; Richard P Phipps
Journal:  Front Immunol       Date:  2015-02-13       Impact factor: 7.561

Review 9.  Non-genomic effects of nuclear receptors: insights from the anucleate platelet.

Authors:  Amanda J Unsworth; Gagan D Flora; Jonathan M Gibbins
Journal:  Cardiovasc Res       Date:  2018-04-01       Impact factor: 10.787

10.  Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells.

Authors:  Christopher Lambers; Christoph Kornauth; Felicitas Oberndorfer; Panja M Boehm; Michael Tamm; Walter Klepetko; Michael Roth
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.